1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,655 | 0,685 | 17:49 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | Ocean Biomedical, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter | 49 | GlobeNewswire (Europe) | PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq... ► Artikel lesen | |
| 17.10. | Ocean Biomedical secures 22% Virion stake with $9 million deal | 1 | Investing.com | ||
| 17.10. | Ocean Biomedical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| OCEAN BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 15.10. | Ocean Biomedical signs $32M pact with Polish biotech for preclinical YKL-40 inhibitors | 2 | FierceBiotech | ||
| 15.10. | Molecure inks $32 million deal with Ocean Biomedical for cancer therapy | 2 | Investing.com | ||
| 15.10. | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 136 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen | |
| 01.10. | Ocean Biomedical, Inc. Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses | 1 | GlobeNewswire (USA) | ||
| 27.08. | Ocean Biomedical, Inc. Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms | 174 | GlobeNewswire (Europe) | Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for... ► Artikel lesen | |
| 23.08. | Ocean Biomedical receives non-compliance notice from Nasdaq | 2 | Seeking Alpha | ||
| 23.08. | Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q | 128 | GlobeNewswire (Europe) | PROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq")... ► Artikel lesen | |
| 23.08. | Ocean Biomedical, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.07. | Ocean Biomedical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Ocean Biomedical, Inc.: Ocean Biomedical Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 | 110 | GlobeNewswire (Europe) | Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists... ► Artikel lesen | |
| 30.05. | Ocean Biomedical, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.05. | Ocean Biomedical gets non-compliance notice from Nasdaq | 2 | Seeking Alpha | ||
| 30.05. | Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q | 162 | GlobeNewswire (Europe) | PROVIDENCE, Rhode Island, May 30, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq")... ► Artikel lesen | |
| 24.04. | Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K | 612 | GlobeNewswire (Europe) | PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq")... ► Artikel lesen | |
| 04.04. | EQT In Exclusive Talks With ICG Infra To Acquire France's Ocea Group | 561 | AFX News | PARIS (dpa-AFX) - Natural gas producer EQT Corp. (EQT) announced Thursday its exclusive talks with ICG Infrastructure Equity I to buy Ocea Group, a French water and heat submetering infrastructure... ► Artikel lesen | |
| 04.04. | EQT enters exclusive talks with ICG Infra to acquire Ocea Group, a leading French water and heat submetering infrastructure provider | 474 | PR Newswire | Ocea is a provider of smart water and heat metering infrastructure in France, operating under long-term inflation-linked contracts in an industry benefiting from long term visibility and... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 10,070 | +1,67 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MEDIGENE | 1,552 | -1,27 % | PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/12.11.2024/13:00)... ► Artikel lesen | |
| 4SC | 4,800 | -8,75 % | 4SC: Bis in das erste Quartal 2026 hinein finanziert | 4SC hat Eckdaten für den Stichtag 30. September 2024 gemeldet. In den ersten neun Monaten habe es im Durchschnitt operativ einen Mittelabfluss von 0,6 Millionen Euro pro Monat gegeben. Dies liegt am... ► Artikel lesen | |
| BIOXXMED | 2,900 | -3,97 % | EQS-Adhoc: bioXXmed AG: Platzierung der Kapitalerhöhung abgeschlossen | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG: Platzierung der Kapitalerhöhung abgeschlossen
01.10.2024 / 17:12 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel... ► Artikel lesen | |
| ORGANOVO | 0,326 | -4,96 % | Organovo reports positive Phase 2 results for liver drug FXR314 | ||
| INOVIO PHARMACEUTICALS | 3,980 | +5,43 % | Inovio Pharmaceuticals Inc. Q3 Loss Narrows | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) reported Loss for third quarter that decreased from last yearThe company's earnings totaled -$25.17 million, or -$0.89 per share. This... ► Artikel lesen | |
| CLINUVEL | 8,075 | -1,04 % | Injecting hope: Clinuvel eyes higher SCENESSE usage in Europe | ||
| SANGAMO THERAPEUTICS | 1,854 | -0,04 % | Sangamo stock climbs 12% post-market on FDA update for ST-503 | ||
| INFLARX | 1,991 | +2,36 % | InflaRx N.V.: InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability | DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| BIO-GATE | 0,720 | 0,00 % | EQS-News: GBC AG: Jetzt noch anmelden: 38. MKK - Münchner Kapitalmarkt Konferenz // zusätzlich präsentieren Bio-Gate AG, Your Family Entertainment AG, Franchetti S.p.A., Lindbergh S.p.A. | EQS-News: GBC AG
/ Schlagwort(e): Konferenz/Sonstiges
Jetzt noch anmelden: 38. MKK - Münchner Kapitalmarkt Konferenz // zusätzlich präsentieren Bio-Gate AG, Your Family Entertainment... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 2,060 | -0,24 % | Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 | Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024
Selected for late-breaking oral presentation at ASN kidney week, the... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,442 | -2,70 % | Cardiol Therapeutics präsentiert klinische Ergebnisse der Phase-II-Pilotstudie MAvERIC zu rezidivierender Perikarditis bei den Scientific Sessions 2024 der American Heart Association | - Eine
deutliche und rasche Reduktion sowohl der Perikarditis-bedingten Schmerzen als auch der Entzündungen wurde während der 26-wöchigen Studie aufrechterhalten
- Anzahl... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,700 | +4,45 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates |
WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen |
Das Unternehmen OCEAN BIOMEDICAL INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,015 (-2,27 %) liegt der Kurs bei 0,645 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OCEAN BIOMEDICAL INC finden Sie auf Wallstreet Online.
